^
    Back
    Association details:
    Biomarker:EGFR mutation + TP53 mutation
    Cancer:Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers

    Published date:
    12/05/2022
    Excerpt:
    Using multivariate analysis, baseline atypical EGFR (mPFS 5.8 mo, p<0.001) and concurrent TP53/RB1 alterations (mPFS 10.5 mo, p=0.015) were associated with shorter progression-free survival on first-line osimertinib.
    DOI:
    https://doi.org/10.1016/j.jtho.2022.11.022